Replies to post #740 on CytoSorbents Corporation (CTSO)

[dr_lowenstein]

Of course, Dr Chan is going to put his product in the best light. Every quote in your post is from him, the CEO of Medasorb. Having said that, I do not disagree with the points he makes, only with the apparent conclusions that you seem to come to. I have not said that hemopurification will not have a role in sepsis, quite to the contrary, I have said that it it works, it will be a nice product for a small company like Medasorb. BUT when some attempt stretch that into multi Billions, it doesnt not pass the smell test.
You said "MIRACLE CURE, EVEN IF IT’S ONLY AN ADJUNCTIVE TREATMENT FOR SEPSIS." That is an oxymoron. See the definition of adjunctive: 1 : something joined or added to another thing but not essentially a part of it from http://www.merriam-webster.com/dictionary/adjunctive

As for the market size, this has been debated and documented extensively in the past. But today only a few points:1. This device,if effective is likely to be used in a subset of the sepsis patients, ie the seriously ill patients in the ICU. That is a much smaller number of patients. and 2. Even if the 18 million number is correct (and it isn't imo), it ignores the reality of the world healthcare market. A substantial number of cases of sepsis occur in the poor, underdeveloped countries of the world. No respectable analyst gives much credence to estimates based on global populations, instead the major pharmaceutical markets are used for this purpose.

Finally, antibiotics have their challenges, but there are nearly 50 clinical trials underway evaluating antibiotics in the sepsis setting see clinicaltrials.gov. Also, the definitive guideline for sepsis treatment: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/?tool=pmcentrez states:We recommend that intravenous antibiotic therapy be started as early as possible and within the first hour of recognition of septic shock (1B) and severe sepsis without septic shock (1D). Appropriate cultures should be obtained before initiating antibiotic therapy, but should not prevent prompt administration of antimicrobial therapy (Grade 1D).